Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series

Affiliations

¹ Joint Rheumatology Program, First Department of Internal Medicine, Propedeutic Clinic, "Laiko" hospital, National and Kapodistrian University of Athens, Athens, Greece geofragoul@yahoo.gr.
² Joint Rheumatology Program, Second Department of Internal Medicine, "Hippokration" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Joint Rheumatology Program, First Department of Internal Medicine, Propedeutic Clinic, "Laiko" hospital, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

^# Contributed equally.

George E Fragoulis et al. Ann Rheum Dis. 2022.

. 2022 Sep 12;81(10):1477-1479.

doi: 10.1136/annrheumdis-2022-222845.

¹ Joint Rheumatology Program, First Department of Internal Medicine, Propedeutic Clinic, "Laiko" hospital, National and Kapodistrian University of Athens, Athens, Greece geofragoul@yahoo.gr.
² Joint Rheumatology Program, Second Department of Internal Medicine, "Hippokration" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Joint Rheumatology Program, First Department of Internal Medicine, Propedeutic Clinic, "Laiko" hospital, National and Kapodistrian University of Athens, Athens, Greece.
⁴ Fourth Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

^# Contributed equally.

No abstract available

Keywords: Autoimmune Diseases; Covid-19; Treatment.

Conflict of interest statement

Competing interests: None declared.